The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Spirina N.N.

Yaroslavl State Medical University

Spirin N.N.

Yaroslavl State Medical University

Dubchenco E.A.

Federal Center of Brain and Neurotechnologies

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies

Effect of different groups of first line DMT on endothelial damage in multiple sclerosis

Authors:

Spirina N.N., Spirin N.N., Dubchenco E.A., Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7‑2): 83‑88

DOI: 10.17116/jnevro202012007283

Read: 2145 times

Download PDF (RU)
Contact the author
Table of contents

EFFECT OF DIFFERENT GROUPS OF FIRST LINE DMT ON ENDOTHELIAL DAMAGE IN MULTIPLE SCLEROSIS
EFFECT OF DIFFERENT GROUPS OF FIRST LINE DMT ON ENDOTHELIAL DAMAGE IN MULTIPLE SCLEROSIS

To cite this article:

Spirina NN, Spirin NN, Dubchenco EA, Boyko AN. Effect of different groups of first line DMT on endothelial damage in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7‑2):83‑88. (In Russ.)
https://doi.org/10.17116/jnevro202012007283

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
Imme­diate resu­lts of medi­cine Slavinorm treatment in patients with athe­rosclerotic arte­ries diseases of the lower extremities. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):102-108
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Correlation between endo­thelial dysfunction and sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2025;(3):13-18
Biomarkers of endo­thelial dysfunction in asse­ssing degrees of the of coro­nary artery disease seve­rity and features of the ischemic heart disease clinical course in middle-aged men. Russian Journal of Preventive Medi­cine. 2025;(6):41-47
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Abstract:

INTRODUCTION

Vascular changes, including destabilization of the blood-brain barrier, are common pathological signs in multiple sclerosis (MS). There are prerequisites, which indicate the direct effects of disease modifying therapy (DMT) on the state of the vascular wall and reduce the damage to the endothelium in MS.

AIM OF THIS STUDY

Was to identify and evaluate the relationship of endothelial dysfunction in patients with multiple sclerosis with used DMT.

MATERIALS AND METHODS

The study included 85 patients with a reliable diagnosis of MS according to the McDonald criteria of 2010 (56 women, 29 men) aged from 17 to 62 years (average age 36.3±1.2 years). All patients underwent a comprehensive clinical and neurological examination, laboratory tests (blood serum analysis for the content of adhesion molecules sICAM-1, sPECAM-1, sE-selectin, sP-selectin, for the content of homocysteine and matrix metalloproteinase 9 (MMR-9) by ELISA; blood plasma analysis for Von Willebrand factor antigen (vWf) by ELISA).

The results of the study indicate a decrease of endothelial damage in MS during interferon therapy. Its also allow the use of indicators such as von Willebrand factor antigen, sPECAM-1, sE-selectin levels as potential markers of the effectiveness of DMT.

Keywords:

multiple sclerosis
endothelial dysfunction
adhesion molecules
immunomodulating therapy

Authors:

Spirina N.N.

Yaroslavl State Medical University

Spirin N.N.

Yaroslavl State Medical University

Dubchenco E.A.

Federal Center of Brain and Neurotechnologies

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies

Received:

14.05.2020

Accepted:

17.05.2020

Close metadata

References:

  1. Gusev EI, Boyko AN. Multiple sclerosis: from the study of immunopathogenesis to new methods of treatment. M.: Gubernskaya medicina; 2001. (In Russ.).
  2. Dyment DA, Yee IM, Ebers GC, Sadovnick AD; Canadian Collaborative Study Group. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry. 2006;77(2):258-259. 
  3. Adams CW, Poston RN, Buk SJ, Sidhu YS, Vipond H. Inflammatory vasculitis in multiple sclerosis. J Neurol Sci. 1985;69(3):269-283. 
  4. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51(2):260-265. 
  5. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol. 1994;35(1):89-97. 
  6. Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence? J Cereb Blood Flow Metab. 2012;32(7):1207-1221. https://doi.org/10.1038/jcbfm.2012.25
  7. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37(4):424-435. 
  8. de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev. 1997;49(2):143-155. 
  9. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9(6):540-549. 
  10. Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, Sasaki M, Alexander JS. Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler. 2003;9(3):235-238. 
  11. Lee BPL, Imhof BA. Lymphocyte transmigration in the brain: a new way of thinking. Nat Immunol. 2008;9(2):117-118. 
  12. Ortiz GG, Pacheco-Moises FP, Macias-Islas MA, Flores-Alvarado LJ, Mireles-Ramirez MA, Gonzales-Renovato ED, Hernandez-Navarro VE, Sanchez-Lopez AL, Alatorre-Jimenez MA. Role of the blood brain barrier in multiple sclerosis. Arch Med Res. 2014;45(8):687-697.  https://doi.org/10.1016/j.arcmed.2014.11.013
  13. Ingrisch M, Sourbron S, Morhard D, Ertl-Wagner B, Kumpfel T, Hohlfeld R, Reiser M, Glaser C. Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T. Invest Radiol. 2012;47(4):252-258.  https://doi.org/10.1097/RLI.0b013e31823bfc97
  14. Gusev EI, Boyko AN, Kolyak EV, Kamchatnov PR, Karalkin AV, Martynov MYu. Contribution of microcirculatory disorders in the formation of the clinical picture of multiple sclerosis after 45 years and possible correction directions. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2008;108(5):84-94. (In Russ.).
  15. Pavlov AU, Bisaga GN, Dean VS, Rud SD, Gaykova ON, Onishchenko LS. Changes in intracerebral vessels and regional cerebral blood flow in multiple sclerosis. Vestnik Rossijskoj Voenno-medicinskoj akademii. 2008;4:66-72. (In Russ.).
  16. Mancini M, Morra VB, Di Donato O, Maglio V, Lanzillo R, Liuzzi R, Salvatore E, Brunetti A, Iaccarino V, Salvatore M. Multiple sclerosis: cerebral circulation time. Radiology. 2012;262(3):947-955.  https://doi.org/10.1148/radiol.11111239
  17. Mancini M, Lanzillo R, Liuzzi R, Di Donato O, Ragucci M, Monti S, Salvatore E, Morra VB, Salvatore M. Internal jugular vein blood flow in multiple sclerosis patients and matched controls. PLoS One. 2014;9(3):e92730. https://doi.org/10.1371/journal.pone.0092730
  18. Spirina NN, Spirin NN, Boyko AN. Endothelial dysfunction in multiple sclerosis and its relationship with pathogenetic therapy. Prakticheskaya medicina. 2013;1-1(68):72-74. (In Russ.).
  19. Spirin NN, Spirina NN, Boyko AN. Von Willebrant factor and adhesion molecules in patients with multiple sclerosis. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014;114:2(2):35-39. (In Russ.).
  20. Spirina NN, Spirin NN, Boyko AN. The effect of pathogenetic therapy on endothelial dysfunction in MS. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115:8(2):84. (In Russ.).
  21. Bogen S, Pak J, Garifallou M, Deng X, Muller W. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med. 1994;179(3):1059-1064.
  22. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S, Ruddle NH, Engelhardt B, Madri JA. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest. 2002;109(3):383-392. 
  23. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65(5):859-873. 
  24. Droogan AG, Crockard AD, McMillan SA, Hawkins SA. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS. Neurology. 1998;50(1):224-229. 
  25. Johnston GI, Bliss GA, Newman PJ, McEver RP. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J Biol Chem. 1990;265(34):21381-21385.
  26. Dufour A, Corsini E, Gelati M, Massa G, Tarcic N, Salmaggi A. In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena. Ann Neurol. 2000;47(5):680-682. 
  27. Mintzer RJ, Croze E, Rubanyi GM, Johns A. Differential effects of IFN-beta1b on the proliferation of human vascular smooth muscle and endothelial cells. J Interferon Cytokine Res. 1998;18(11):939-945. 
  28. Takano S, Ishikawa E, Matsuda M, Yamamoto T, Matsumura A. Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol. 2014;45(5):1837-1846. https://doi.org/10.3892/ijo.2014.2620
  29. Bernal F, Elias B, Hartung HP, Kieseir BC. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in MS patients. Mult Scler. 2009;15(6):721-727.  https://doi.org/10.1177/1352458509102920
  30. Fernandes KS, Brum DG, Palei AC, Sandrim VC, Guerreiro CT, Tanus-Santos JE, Barreira AA. Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients. J Neuroimmunol. 2012;249(1-2):56-59.  https://doi.org/10.1016/j.jneuroim.2012.04.001
  31. Szklarczyk A, Conant K. Matrix metalloproteinases, synaptic injury, and multiple sclerosis. Front Psychiatry. 2010;1:130.  https://doi.org/10.3389/fpsyt.2010.00130
  32. Zahednasab H, Saadatnia M, Jabalameli MR, Zarkesh-Esfahani H, Esmaeili A, Bahreini SA. Controversial role of MMP-9 gene in MS disease. J Neuroimmunol. 2011;230(1-2):191.  https://doi.org/10.1016/j.jneuroim.2010.09.006
  33. Cox MB, Bowden NA, Scott RJ, Lechner-Scott J. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. Mult Scler. 2013;19(10):1268-1274. https://doi.org/10.1177/1352458513475493
  34. Boyko AN, Tatarinova MY, Alekseeva T.G., Smirnova NF, Kulakova JG, Slanova AV, Favorova OO, Gusev EI. Monitoring of the level of matrix metalloproteinase 9 in assessing the clinical and biological effects of beta-interferon in relapsing-remitting multiple sclerosis. Nejroimmunologia, Issledovania, Clinica, Lechenie. 2002;28-30. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.